US FDA authorizes Novavax Covid vaccine for adults | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Thursday
December 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
THURSDAY, DECEMBER 07, 2023
US FDA authorizes Novavax Covid vaccine for adults

Coronavirus chronicle

Reuters
14 July, 2022, 10:05 am
Last modified: 14 July, 2022, 10:06 am

Related News

  • Moderna says updated Covid vaccine is effective against newer variant
  • Acme's muscle relaxant tablet 'Chlorzoxazone 500' gets US FDA approval
  • Vaccine maker Novavax says 'substantial doubt' over future
  • US FDA says India-made eye drop linked to some infections, blindness and one death
  • Incepta Pharma abandons Covid vaccine plan

US FDA authorizes Novavax Covid vaccine for adults

Reuters
14 July, 2022, 10:05 am
Last modified: 14 July, 2022, 10:06 am
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. Photo: Reuters
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. Photo: Reuters

The US Food and Drug Administration authorized the use of Novavax Inc's Covid-19 vaccine on Wednesday, clearing the way for a shot whose more traditional technology has raised hopes of wider acceptance among vaccine skeptics.

Shares of Novavax rose 1.3% to $70.89 after its two-dose vaccine became the fourth Covid shot to be authorized for use in adults in the United States.

The US Centers for Disease Control and Prevention (CDC) still needs to sign off on the use of the vaccine before it can be made available to people.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

A panel of CDC advisers on vaccines is expected to meet on Tuesday, but the agenda has not been released yet.

Earlier this week, the US government said it had secured 3.2 million Novavax vaccine doses, which it plans to release once the company finishes quality testing in the next few weeks.

More than two-thirds of the US population has been fully vaccinated with shots from Moderna Inc, Pfizer-BioNTech, or Johnson & Johnson.

US health officials hope that people who have opted not to take Pfizer and Moderna's vaccine, which are based on the groundbreaking messenger RNA (mRNA) technology, will instead opt for Novavax's protein-based shot.

The vaccine, already approved in Europe, is based on a technology that has been used for decades to combat diseases including hepatitis B and influenza.

"Today's authorization offers adults in the United States who have not yet received a Covid-19 vaccine another option that meets the FDA's rigorous standards," FDA Commissioner Robert Califf said in a statement.

In Europe, however, demand for the shot has not been significantly high, with about 242,000 doses of the vaccine administered since its launch in December, prompting Novavax to increase its focus on lower-income countries.

The company's initial application for US authorization of the shot was delayed by almost a year on development and production problems, making it a late entrant in the country's market for Covid vaccines.

Novavax has projected between $4 billion and $5 billion in sales this year. Analysts expect sales at the lower end of that range, according to Refinitiv.

World+Biz / USA

Novavax / Novavax Covid-19 Vaccine / Novavax Inc / Novavax vaccine / Covid vaccine / US FDA Approval / US FDA

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Deepening dollar crisis in Bangladesh: Unveiling causes and solutions
    Deepening dollar crisis in Bangladesh: Unveiling causes and solutions
  • BNP Secretary General Mirza Fakhrul Islam Alamgir
    HC denies Fakhrul's bail, issues rule asking why he should not get bail
  • File Photo of Jatiya Party Secretary General Mujibul Haque Chunnu
    Jatiya Party reassured about fair polls after discussion with Awami League: Chunnu

MOST VIEWED

  • Bangladeshi RMG exporters alarmed as buyers tag conditions over trade restriction fears
    Bangladeshi RMG exporters alarmed as buyers tag conditions over trade restriction fears
  • Illustration: TBS
    Troubled banks categorised, new deposits, loans barred for weakest
  • File Photo of the US Ambassador to Bangladesh Peter Haas. Photo: Collected
    US Ambassador Peter Haas holds meeting with Biman officials
  • Bank deposits in Bangladesh surge on higher interest, lower investment
    Bank deposits in Bangladesh surge on higher interest, lower investment
  • Photo: AFP
    Bangladesh lose 4 wickets after decent start in first session
  • Illustration: TBS
    Cenbank doubles limit for sending remittances to MFS accounts

Related News

  • Moderna says updated Covid vaccine is effective against newer variant
  • Acme's muscle relaxant tablet 'Chlorzoxazone 500' gets US FDA approval
  • Vaccine maker Novavax says 'substantial doubt' over future
  • US FDA says India-made eye drop linked to some infections, blindness and one death
  • Incepta Pharma abandons Covid vaccine plan

Features

Hamas-Israel war: What really happened on 7 October?

Hamas-Israel war: What really happened on 7 October?

4h | Panorama
UN workers arrive to distribute aid to Palestinians, who have fled their homes due to Israeli strikes and take shelter in a UN-run school, in Khan Younis in the southern Gaza Strip on 23 October 2023. Photo: Reuters

When UN and its agencies lack much agency

4h | Panorama
Sketch: TBS

How Khan Farhana built a 300,000-strong LinkedIn community

15h | Pursuit
Photo: Courtesy

Fostering emotional intelligence and classroom harmony: The power of a complaint box

15h | Pursuit

More Videos from TBS

Messi named Time Magazine's 'Athlete of the Year'

Messi named Time Magazine's 'Athlete of the Year'

39m | TBS SPORTS
What is 'obstructing the field' out?

What is 'obstructing the field' out?

20h | TBS SPORTS
When Farooki is hero

When Farooki is hero

18h | TBS Entertainment
Losing uteruses to the climate crisis in coastal Bangladesh

Losing uteruses to the climate crisis in coastal Bangladesh

2h | TBS Stories
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]